Global Netherton Syndrome Market Size, Trends & Growth Opportunities to 2027: A 20% Compound Annual Growth Rate is Forecast During 2021 to 2027 – ResearchAndMarkets.com

Global Netherton Syndrome Market Size, Trends & Growth Opportunities to 2027: A 20% Compound Annual Growth Rate is Forecast During 2021 to 2027 – ResearchAndMarkets.com




Global Netherton Syndrome Market Size, Trends & Growth Opportunities to 2027: A 20% Compound Annual Growth Rate is Forecast During 2021 to 2027 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Netherton syndrome market Size, Trends & Growth Opportunity, By Therapy, Region and Forecast to 2027” report has been added to ResearchAndMarkets.com’s offering.

The Netherton syndrome market is expected to reach US$ 74.31 million by 2027 from US$ 19.57 million in 2019; it is estimated to grow at a CAGR of 20.3% from 2021 to 2027.

The market is witnessing major growth due to the increasing awareness regarding Netherton syndrome and growing number of product introductions. Awareness campaigns are being considered to be helpful in means of enabling timely and accurate diagnosis as well as social and various medical organizations are working towards spreading awareness. Moreover, rising number of clinical trials and robust pipeline of products act as significant opportunities for the future growth of the market players.

However, the risk of adverse reactions associated with the Netherton syndrome treatment drugs restrains the growth of the market. Through which people will stop with awareness campaigns which will affect various organizations.

Globally the market is segmented on the basis of therapy. By therapy, market is segmented into keratolytic agents, oral and topical steroids and retinoid, topical calcineurin inhibitors, biological therapies, and radiation therapies. The biological therapy segment is estimated to register the highest CAGR in the market during the forecast period. Market growth for the biological therapy segment is assigned to the increasing adoption of biological therapy due to its beneficial treatment outcomes whereas the growth of keratolytic segment is attributed to the increased product launches and robust existing product pipeline.

COVID-19 recovery and resuming the healthcare improvement journey is at the forefront of 2021 healthcare trends in Asia-Pacific (APAC) countries such as India, China, and Japan, as they are around the world. However, the APAC region’s combination of industrialized and developing countries presents distinct issues, as healthcare access and basic infrastructure differ significantly between urban and rural populations and economic levels.

Industry development

  • In 2019, the keratolytic agents segment held the largest share of the global Netherton syndrome market.
  • In May 2020, Azitra, Inc., a clinical-stage medical dermatology drug manufacturer, received Rare Pediatric Disease Designation to ATR-12 from the US Food and Drug Administration for the treatment of Netherton syndrome.

Key Questions Addressed by the Report?

  • What are the driving factors for the Netherton syndrome market across the globe?
  • Who are the major players in the Netherton syndrome market?
  • What would be the Netherton Syndrome total market Size and market Size by therapies across the globe during the forecast period (2021-2027)?

     

     

Key Topics Covered:

1 Introduction

2 Research Methodology

3 Executive Summary

4 Global Netherton Syndrome Market Outlook

5 Global Netherton Syndrome Market, By Therapy

6. Global Netherton Syndrome Market, By Region

8. North America Netherton Syndrome Market Analysis and Forecast (2021-2027)

9. Europe Netherton Syndrome Market Analysis and Forecast (2021-2027)

10. Asia Pacific Netherton Syndrome Market Analysis and Forecast (2021-2027)

11. Latin America Netherton Syndrome Market Analysis and Forecast (2021-2027)

12. Middle East Netherton Syndrome Market Analysis and Forecast (2021-2027)

13 Competitive Analysis

13.1 Competition Dashboard

13.2 Market share Analysis of Top Vendors

13.3 Key Development Strategies

14 Company Profiles

  • Lifemax Laboratories Inc.
  • Azitra Inc.
  • Sixera Pharma Ab
  • Dermelix Biotherapeutics
  • Matrisys Bioscience
  • Quoin Pharmaceuticals Ltd.
  • Krystal Biotech Inc.

     

For more information about this report visit https://www.researchandmarkets.com/r/8aills

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900